Clevudine
| Title | Journal |
|---|---|
| Noncompetitive inhibition of hepatitis B virus reverse transcriptase protein priming and DNA synthesis by the nucleoside analog clevudine. | Antimicrobial agents and chemotherapy 20130901 |
| Microwave-assisted one-pot radiosynthesis of 2'-deoxy-2'-[18F]fluoro-5-methyl-1-β-d-arabinofuranosyluracil ([18F]-FMAU). | Nuclear medicine and biology 20121001 |
| Simultaneous determination of 1-(2'-deoxy-2'-fluoro-β-D-arabinofuranosyl) uracil (FAU) and 1-(2'-deoxy-2'-fluoro-β-D-arabinofuranosyl) 5-methyluracil (FMAU) in human plasma by liquid chromatography/tandem mass spectrometry. | Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 20120401 |
| [New drugs of treatment of patients with chronic hepatitis B]. | Nihon rinsho. Japanese journal of clinical medicine 20120401 |
| Normal-phase liquid chromatography coupled with electrospray ionization mass spectrometry for chiral separation and quantification of clevudine and its enantiomer in human plasma. | Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 20120215 |
| Structure-guided engineering of human thymidine kinase 2 as a positron emission tomography reporter gene for enhanced phosphorylation of non-natural thymidine analog reporter probe. | The Journal of biological chemistry 20120102 |
| High-dose clevudine impairs mitochondrial function and glucose-stimulated insulin secretion in INS-1E cells. | BMC gastroenterology 20120101 |
| [18F]-2'-Fluoro-5-methyl-1-beta-D-arabinofuranosyluracil (18F-FMAU) in prostate cancer: initial preclinical observations. | Molecular imaging 20120101 |
| [New drugs of treatment of patients with chronic hepatitis B]. | Nihon rinsho. Japanese journal of clinical medicine 20110501 |
| Virologic and biochemical responses to clevudine in patients with chronic HBV infection-associated cirrhosis: data at week 48. | Journal of viral hepatitis 20110401 |
| 18F-FDG PET/CT of drug-induced myopathy in a patient with chronic hepatitis B on long-term clevudine therapy. | European journal of nuclear medicine and molecular imaging 20110401 |
| Clevudine-induced viral response, associated with continued reduction of HBsAg titer, was durable after the withdrawal of therapy. | Journal of gastroenterology 20110301 |
| Clevudine for chronic hepatitis B: antiviral response, predictors of response, and development of myopathy. | Journal of viral hepatitis 20110201 |
| Automated synthesis of 2'-deoxy-2'-[18F]fluoro-5-methyl-1-β-D-arabinofuranosyluracil ([18F]-FMAU) using a one reactor radiosynthesis module. | Nuclear medicine and biology 20110201 |
| Comparison of clevudine and entecavir for treatment-naive patients with chronic hepatitis B virus infection: two-year follow-up data. | Journal of clinical gastroenterology 20110101 |
| [Treatment efficacy of clevudine, entecavir and lamivudine in treatment-naive patients with HBeAg-positive chronic hepatitis B]. | The Korean journal of gastroenterology = Taehan Sohwagi Hakhoe chi 20101201 |
| Efficacy of initial treatment with clevudine in naive patients with chronic hepatitis B. | The Korean journal of internal medicine 20101201 |
| Different modes of transport for 3H-thymidine, 3H-FLT, and 3H-FMAU in proliferating and nonproliferating human tumor cells. | Journal of nuclear medicine : official publication, Society of Nuclear Medicine 20100901 |
| Forty-eight weeks treatment with clevudine 30 mg qd versus lamivudine 100 mg qd for chronic hepatitis B infection: a double-blind randomized study. | The Korean journal of hepatology 20100901 |
| Clinical, biochemical, and pathological characteristics of clevudine-associated myopathy. | Journal of hepatology 20100801 |
| Focus. | Journal of hepatology 20100801 |
| Comparison between clevudine and entecavir treatment for antiviral-naïve patients with chronic hepatitis B. | Liver international : official journal of the International Association for the Study of the Liver 20100701 |
| Treatment outcomes of clevudine versus lamivudine at week 48 in naïve patients with HBeAg positive chronic hepatitis B. | Journal of Korean medical science 20100501 |
| Clevudine demonstrates potent antiviral activity in naïve chronic hepatitis B patients. | Intervirology 20100101 |
| Polymyositis in patients taking antiviral clevudine therapy: a report of two cases. | NeuroRehabilitation 20100101 |
| Evaluation of the in vitro anti-HBV activity of clevudine in combination with other nucleoside/nucleotide inhibitors. | Antiviral therapy 20100101 |
| Clevudine myopathy in patients with chronic hepatitis B. | Journal of hepatology 20091001 |
| Myopathy and neuropathy associated with nucleos(t)ide analog therapy for hepatitis B. | Journal of hepatology 20091001 |
| [Efficacy of 48-week clevudine therapy for chronic hepatitis B]. | The Korean journal of hepatology 20090901 |
| Early development of clevudine resistance during clevudine therapy in a patient with chronic hepatitis B who received prior lamivudine therapy. | Liver international : official journal of the International Association for the Study of the Liver 20090701 |
| Long-term therapy with clevudine for chronic hepatitis B can be associated with myopathy characterized by depletion of mitochondrial DNA. | Hepatology (Baltimore, Md.) 20090601 |
| [Clevudine therapy in patients with chronic hepatitis B]. | The Korean journal of hepatology 20090601 |
| [Long-term clevudine therapy in nucleos(t)ide-naïve and lamivudine-experienced patients with hepatitis B virus-related chronic liver diseases]. | The Korean journal of hepatology 20090601 |
| [New molecules in the treatment of chronic hepatitis B]. | Presse medicale (Paris, France : 1983) 20090501 |
| Clevudine for hepatitis B. | Drugs of today (Barcelona, Spain : 1998) 20090501 |
| Clinical and virological responses to clevudine therapy in chronic hepatitis B patients: results at 1 year of an open-labelled prospective study. | Antiviral therapy 20090101 |
| Clevudine: a promising therapy for the treatment of chronic hepatitis B. | Expert opinion on investigational drugs 20081201 |
| [Development of clevudine resistance after switching from lamivudine in a patient with chronic hepatitis B]. | The Korean journal of gastroenterology = Taehan Sohwagi Hakhoe chi 20081101 |
| Tracking cellular stress with labeled FMAU reflects changes in mitochondrial TK2. | European journal of nuclear medicine and molecular imaging 20080801 |
| Clinical trial: a phase II, randomized study evaluating the safety, pharmacokinetics and anti-viral activity of clevudine for 12 weeks in patients with chronic hepatitis B. | Alimentary pharmacology & therapeutics 20080601 |
| [Management of chronic hepatitis B in treatment-naive patients]. | The Korean journal of gastroenterology = Taehan Sohwagi Hakhoe chi 20080601 |
| [Management of antiviral-resistant chronic hepatitis B virus infection]. | The Korean journal of gastroenterology = Taehan Sohwagi Hakhoe chi 20080601 |
| Evaluation of 2'-deoxy-2'-[18F]fluoro-5-methyl-1-beta-L: -arabinofuranosyluracil ([18F]-L: -FMAU) as a PET imaging agent for cellular proliferation: comparison with [18F]-D: -FMAU and [18F]FLT. | European journal of nuclear medicine and molecular imaging 20080501 |
| In vivo measurement of cell proliferation in canine brain tumor using C-11-labeled FMAU and PET. | Nuclear medicine and biology 20080101 |
| New drugs for chronic hepatitis B: a review. | American journal of therapeutics 20080101 |
| Clevudine is efficiently phosphorylated to the active triphosphate form in primary human hepatocytes. | Antiviral therapy 20080101 |
| Clevudine is highly efficacious in hepatitis B e antigen-negative chronic hepatitis B with durable off-therapy viral suppression. | Hepatology (Baltimore, Md.) 20071001 |
| Tumor imaging using 1-(2'-deoxy-2'-18F-fluoro-beta-D-arabinofuranosyl)thymine and PET. | Journal of nuclear medicine : official publication, Society of Nuclear Medicine 20070901 |
| Radiosynthesis of 2'-deoxy-2'-[18F]-fluoro-5-methyl-1-beta-L-arabinofuranosyluracil ([18F]-L-FMAU) for PET. | Applied radiation and isotopes : including data, instrumentation and methods for use in agriculture, industry and medicine 20070801 |
| 6-Chloro-3-(((1-[11C]methyl)-2-(S)-pyrrolidinyl)methoxy)-5-(2-fluoropyridin-4-yl)pyridine ([11C]JHU85270), a potent ligand for nicotinic acetylcholine receptor imaging by positron emission tomography. | Applied radiation and isotopes : including data, instrumentation and methods for use in agriculture, industry and medicine 20070801 |
| Twenty-four-week clevudine therapy showed potent and sustained antiviral activity in HBeAg-positive chronic hepatitis B. | Hepatology (Baltimore, Md.) 20070501 |
| Clevudine therapy for 24 weeks further reduced serum hepatitis B virus DNA levels and increased ALT normalization rates without emergence of viral breakthrough than 12 weeks of clevudine therapy. | Intervirology 20070101 |
| A novel mutation pattern emerging during lamivudine treatment shows cross-resistance to adefovir dipivoxil treatment. | Antiviral therapy 20070101 |
| Hepatitis B virus treatment in HIV-infected patients. | Topics in HIV medicine : a publication of the International AIDS Society, USA 20061201 |
| Clevudine: a potent inhibitor of hepatitis B virus in vitro and in vivo. | Expert review of anti-infective therapy 20060801 |
| [Advances in the study of nucleoside antiviral drugs]. | Yao xue xue bao = Acta pharmaceutica Sinica 20060801 |
| A 12-week clevudine therapy showed potent and durable antiviral activity in HBeAg-positive chronic hepatitis B. | Hepatology (Baltimore, Md.) 20060501 |
| [Therapeutic approach to EBV infection]. | Nihon rinsho. Japanese journal of clinical medicine 20060301 |
| Cellular and virological mechanisms of HBV drug resistance. | Journal of hepatology 20060201 |
| Rapid quantitative determination of L-FMAU-TP from human peripheral-blood mononuclear cells of hepatitis B virus-infected patients treated with L-FMAU by ion-pairing, reverse-phase, liquid chromatography/electrospray tandem mass spectrometry. | Therapeutic drug monitoring 20060201 |
| Clevudine for the treatment of chronic hepatitis B virus infection. | Expert opinion on investigational drugs 20051001 |
| Combination of nucleoside analogues in the treatment of chronic hepatitis B virus infection: lesson from experimental models. | The Journal of antimicrobial chemotherapy 20050501 |
| Imaging DNA synthesis in vivo with 18F-FMAU and PET. | Journal of nuclear medicine : official publication, Society of Nuclear Medicine 20050201 |
| Imaging DNA synthesis with [18F]FMAU and positron emission tomography in patients with cancer. | European journal of nuclear medicine and molecular imaging 20050101 |
| Drugs in development for hepatitis B. | Drugs 20050101 |
| Comparison of [14C]FMAU, [3H]FEAU, [14C]FIAU, and [3H]PCV for monitoring reporter gene expression of wild type and mutant herpes simplex virus type 1 thymidine kinase in cell culture. | Molecular imaging and biology : MIB : the official publication of the Academy of Molecular Imaging 20050101 |
| Clevudine therapy with vaccine inhibits progression of chronic hepatitis and delays onset of hepatocellular carcinoma in chronic woodchuck hepatitis virus infection. | Antiviral therapy 20041201 |
| Distribution of 1-(2-deoxy-2-fluoro-beta-D-arabinofuranosyl) uracil in mice bearing colorectal cancer xenografts: rationale for therapeutic use and as a positron emission tomography probe for thymidylate synthase. | Clinical cancer research : an official journal of the American Association for Cancer Research 20041001 |
| Adenovirus-based gene therapy during clevudine treatment of woodchucks chronically infected with woodchuck hepatitis virus. | Virology 20040915 |
| A phase II dose-escalating trial of clevudine in patients with chronic hepatitis B. | Hepatology (Baltimore, Md.) 20040701 |
| [New approaches in the treatment of hepatitis B]. | Deutsche medizinische Wochenschrift (1946) 20040521 |
| Pharmacokinetics of the thymidine analog 2'-fluoro-5-methyl-1-beta-D-arabinofuranosyluracil (FMAU) in tumor-bearing rats. | Nuclear medicine and biology 20040501 |
| Direct comparison of radiolabeled probes FMAU, FHBG, and FHPG as PET imaging agents for HSV1-tk expression in a human breast cancer model. | Molecular imaging 20040401 |
| New treatment of chronic hepatitis B. | Seminars in liver disease 20040101 |
| Monitoring tumor cell proliferation by targeting DNA synthetic processes with thymidine and thymidine analogs. | Journal of nuclear medicine : official publication, Society of Nuclear Medicine 20031201 |
| Mechanism of antiviral activities of 3'-substituted L-nucleosides against 3TC-resistant HBV polymerase: a molecular modelling approach. | Antiviral chemistry & chemotherapy 20031101 |
| Effects of pyrimidine and purine analog combinations in the duck hepatitis B virus infection model. | Antimicrobial agents and chemotherapy 20030601 |
| Synthesis of 2'-deoxy-2'-[18F]fluoro-beta-D-arabinofuranosyl nucleosides, [18F]FAU, [18F]FMAU, [18F]FBAU and [18F]FIAU, as potential PET agents for imaging cellular proliferation. Synthesis of [18F]labelled FAU, FMAU, FBAU, FIAU. | Nuclear medicine and biology 20030401 |
| Current and future antiviral agents for chronic hepatitis B. | The Journal of antimicrobial chemotherapy 20030301 |
| Comparison of anti-hepatitis B virus activities of lamivudine and clevudine by a quantitative assay. | Antimicrobial agents and chemotherapy 20030101 |
| In vitro activity of potential anti-poxvirus agents. | Antiviral research 20030101 |
| Entecavir, FTC, L-FMAU, LdT and others. | Journal of hepatology 20030101 |
| Treatment of HBeAg negative chronic hepatitis B with new drugs (adefovir and others). | Journal of hepatology 20030101 |
| Understanding the unique mechanism of L-FMAU (clevudine) against hepatitis B virus: molecular dynamics studies. | Bioorganic & medicinal chemistry letters 20021202 |
| Rat studies comparing 11C-FMAU, 18F-FLT, and 76Br-BFU as proliferation markers. | Journal of nuclear medicine : official publication, Society of Nuclear Medicine 20021201 |
| Inhibitory activity of dioxolane purine analogs on wild-type and lamivudine-resistant mutants of hepadnaviruses. | Hepatology (Baltimore, Md.) 20020901 |
| Radiolabeled 2'-fluorodeoxyuracil-beta-D-arabinofuranoside (FAU) and 2'-fluoro-5-methyldeoxyuracil-beta -D-arabinofuranoside (FMAU) as tumor-imaging agents in mice. | Cancer chemotherapy and pharmacology 20020501 |
| [New management strategies for hepatitis B]. | Gastroenterologie clinique et biologique 20020201 |
| New synthesis of L-FMAU from L-arabinose. | Nucleosides, nucleotides & nucleic acids 20020101 |
| Immunogenic effects of woodchuck hepatitis virus surface antigen vaccine in combination with antiviral therapy: breaking of humoral and cellular immune tolerance in chronic woodchuck hepatitis virus infection. | Intervirology 20020101 |
| Evaluation of 2'-deoxy-2'-flouro-5-methyl-1-beta-D-arabinofuranosyluracil as a potential gene imaging agent for HSV-tk expression in vivo. | Molecular imaging 20020101 |
| Rapid enantiomeric quantification of an antiviral nucleoside agent (D,L-FMAU, 2'-fluoro-5-methyl-beta,D,L-arabinofurano-syluracil) by mass spectrometry. | Journal of medicinal chemistry 20011025 |
| In vitro susceptibilities of wild-type or drug-resistant hepatitis B virus to (-)-beta-D-2,6-diaminopurine dioxolane and 2'-fluoro-5-methyl-beta-L-arabinofuranosyluracil. | Antimicrobial agents and chemotherapy 20010901 |
| Antiviral activity of clevudine [L-FMAU, (1-(2-fluoro-5-methyl-beta, L-arabinofuranosyl) uracil)] against woodchuck hepatitis virus replication and gene expression in chronically infected woodchucks (Marmota monax). | Hepatology (Baltimore, Md.) 20010101 |
| Potential use of antiviral L(-)nucleoside analogues for the prevention or treatment of viral associated cancers. | Cancer letters 20010101 |
| Structure-activity relationships of L-dioxolane uracil nucleosides as anti-Epstein Barr virus agents. | Journal of medicinal chemistry 19990617 |
| Sensitivity of L-(-)2,3-dideoxythiacytidine resistant hepatitis B virus to other antiviral nucleoside analogues. | Biochemical pharmacology 19990615 |
| Synthesis and anti-hepatitis B virus activity of 9-(2-deoxy-2-fluoro-beta-L-arabinofuranosyl) purine nucleosides. | Journal of medicinal chemistry 19970815 |
| Structure--activity relationships of 1-(2-Deoxy-2-fluoro-beta-L-arabinofuranosyl)pyrimidine nucleosides as anti-hepatitis B virus agents. | Journal of medicinal chemistry 19960705 |
| Inhibition of Epstein-Barr virus replication by a novel L-nucleoside, 2'-fluoro-5-methyl-beta-L-arabinofuranosyluracil. | Biochemical pharmacology 19960412 |
| Inhibition of hepatitis B virus by a novel L-nucleoside, 2'-fluoro-5-methyl-beta-L-arabinofuranosyl uracil. | Antimicrobial agents and chemotherapy 19960201 |
| Inhibitory effects of 2'-fluorinated arabinosyl-pyrimidine nucleosides on woodchuck hepatitis virus replication in chronically infected woodchucks. | Antimicrobial agents and chemotherapy 19900301 |
| Activity of 1-(2'-deoxy-2'-fluoro-beta-D-arabinofuranosyl)-5-iodouracil against simian varicella virus infections in African green monkeys. | Antimicrobial agents and chemotherapy 19860101 |
| Comparative anti-herpesvirus activities of 9-(1,3-dihydroxy-2-propoxymethyl)guanine, acyclovir, and two 2'-fluoropyrimidine nucleosides. | Antiviral research 19851001 |
| Therapeutic activities of 1-(2-fluoro-2-deoxy-beta-D-arabinofuranosyl)-5-iodocytosine and -thymine alone and in combination with acyclovir and vidarabine in mice infected intracerebrally with herpes simplex virus. | Antimicrobial agents and chemotherapy 19830701 |
| Activity of 1-(2'-fluoro-2'-deoxy-beta-D-arabinofuranosyl)thymine against herpes simplex virus in cell cultures and rabbit eyes. | Antimicrobial agents and chemotherapy 19830601 |